Salles GA et al. Efficacy and safety of obinutuzumab (GA101) monotherapy in relapsed/refractory indolent non-Hodgkin’s lymphoma: Results from a Phase I/II study (BO20999). Proc ASH 2011;Abstract 268.

Sehn LH et al. Randomized Phase II trial comparing GA101 (obinutuzumab) with rituximab in patients with relapsed CD20+ indolent B-cell non‑Hodgkin lymphoma: Preliminary analysis of the GAUSS study. Proc ASH 2011;Abstract 269.

Radford J et al. Obinutuzumab (GA101) in combination with FC or CHOP in patients with relapsed or refractory follicular lymphoma: Final results of the Phase I GAUDI study (BO21000). Proc ASH 2011;Abstract 270.

Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division of the James P Wilmot Cancer Center at the University of Rochester in Rochester, New York.

Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Director for Clinical Research at UW Carbone Cancer Center in Madison, Wisconsin.